-+ 0.00%
-+ 0.00%
-+ 0.00%

Insight Molecular Diagnostics Publishes Q3 2026 Earnings Call Transcript

PUBT·11/19/2026 03:54:01
Insight Molecular Diagnostics Publishes Q3 2026 Earnings Call Transcript
  • Insight Molecular Diagnostics held its Nov. 16 third-quarter 2026 earnings call with CEO Joshua Riggs, CFO Andrea James and CSO Ekke Schütz.
  • Management expects to complete additional GraftAssureDx studies by year-end and submit its FDA response before the Jan. 21, 2027, deadline.
  • About 75 FDA review days remain; launch is planned immediately following authorization, though the agency could extend its review.
  • GALACTIC registry enrollment has begun, but management expects limited near-term revenue from the registry and beta-site programs.
  • Research and development expenses fell to $3.8 million from their fourth-quarter 2025 peak of $5.8 million as FDA program spending declined.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.